Navann Ty
Stock Analyst at Exane BNP Paribas
(3.23)
# 2,444
Out of 4,456 analysts
39
Total ratings
55.6%
Success rate
7.2%
Average return
Main Sectors:
Stocks Rated by Navann Ty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OGN Organon & Co. | Downgraded: Hold | $15 → $14 | $13.50 | +3.70% | 6 | Apr 28, 2026 | |
| MDLN Medline | Initiated Coverage: Hold | $38 | $38.87 | -2.24% | 1 | Jan 12, 2026 | |
| NTRA Natera | Upgraded: Hold | $28 → $172 | $261.91 | -34.33% | 2 | Oct 27, 2025 | |
| GEHC GE HealthCare Technologies | Reiterated: Buy | $92 | $65.76 | +39.90% | 1 | Sep 10, 2025 | |
| PAHC Phibro Animal Health | Maintained: Hold | $24 → $37 | $31.69 | +16.76% | 2 | Sep 4, 2025 | |
| COO The Cooper Companies | Upgraded: Buy | $92 | $71.02 | +29.54% | 1 | Jul 22, 2025 | |
| KVUE Kenvue | Initiated Coverage: Hold | $28 | $19.13 | n/a | 1 | May 30, 2023 | |
| SKIN SkinHealth Systems | Upgraded: Hold | n/a | $0.66 | n/a | 2 | Mar 20, 2023 | |
| ABBV AbbVie | Initiated Coverage: Hold | $169 | $253.35 | n/a | 1 | Dec 8, 2022 | |
| EOLS Evolus | Initiated Coverage: Buy | $13 | $7.13 | n/a | 1 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $22 → $26 | $55.08 | n/a | 2 | Mar 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $16 → $11 | $16.33 | n/a | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $232 → $208 | $76.09 | n/a | 6 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $200 | $230.02 | n/a | 1 | Oct 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $39 → $42 | $24.57 | n/a | 6 | May 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37.02 → $52.68 | $6.77 | n/a | 3 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $10 | $33.21 | n/a | 1 | Apr 24, 2020 |
Organon & Co.
Apr 28, 2026
Downgraded: Hold
Price Target: $15 → $14
Current: $13.50
Upside: +3.70%
Medline
Jan 12, 2026
Initiated Coverage: Hold
Price Target: $38
Current: $38.87
Upside: -2.24%
Natera
Oct 27, 2025
Upgraded: Hold
Price Target: $28 → $172
Current: $261.91
Upside: -34.33%
GE HealthCare Technologies
Sep 10, 2025
Reiterated: Buy
Price Target: $92
Current: $65.76
Upside: +39.90%
Phibro Animal Health
Sep 4, 2025
Maintained: Hold
Price Target: $24 → $37
Current: $31.69
Upside: +16.76%
The Cooper Companies
Jul 22, 2025
Upgraded: Buy
Price Target: $92
Current: $71.02
Upside: +29.54%
Kenvue
May 30, 2023
Initiated Coverage: Hold
Price Target: $28
Current: $19.13
Upside: n/a
SkinHealth Systems
Mar 20, 2023
Upgraded: Hold
Price Target: n/a
Current: $0.66
Upside: n/a
AbbVie
Dec 8, 2022
Initiated Coverage: Hold
Price Target: $169
Current: $253.35
Upside: n/a
Evolus
Dec 8, 2022
Initiated Coverage: Buy
Price Target: $13
Current: $7.13
Upside: n/a
Mar 22, 2022
Maintained: Hold
Price Target: $22 → $26
Current: $55.08
Upside: n/a
Mar 10, 2022
Maintained: Hold
Price Target: $16 → $11
Current: $16.33
Upside: n/a
Mar 9, 2022
Maintained: Hold
Price Target: $232 → $208
Current: $76.09
Upside: n/a
Oct 5, 2021
Initiated Coverage: Buy
Price Target: $200
Current: $230.02
Upside: n/a
May 17, 2021
Maintained: Buy
Price Target: $39 → $42
Current: $24.57
Upside: n/a
Mar 2, 2021
Maintained: Buy
Price Target: $37.02 → $52.68
Current: $6.77
Upside: n/a
Apr 24, 2020
Initiated Coverage: Hold
Price Target: $10
Current: $33.21
Upside: n/a